nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Fluorouracil—head and neck cancer	0.186	0.393	CbGbCtD
Leflunomide—ABCG2—Docetaxel—head and neck cancer	0.142	0.3	CbGbCtD
Leflunomide—CYP1A2—Fluorouracil—head and neck cancer	0.0769	0.162	CbGbCtD
Leflunomide—CYP2C9—Fluorouracil—head and neck cancer	0.0693	0.146	CbGbCtD
Leflunomide—Niflumic Acid—PTGS2—head and neck cancer	0.00373	1	CrCbGaD
Leflunomide—Neoplasm—Vinblastine—head and neck cancer	0.0022	0.00876	CcSEcCtD
Leflunomide—Foetor hepaticus—Docetaxel—head and neck cancer	0.00204	0.00809	CcSEcCtD
Leflunomide—Rash maculo-papular—Hydroxyurea—head and neck cancer	0.00202	0.00803	CcSEcCtD
Leflunomide—Neoplasm—Hydroxyurea—head and neck cancer	0.00201	0.00799	CcSEcCtD
Leflunomide—Tingling sensation—Fluorouracil—head and neck cancer	0.00199	0.00791	CcSEcCtD
Leflunomide—Polyp—Docetaxel—head and neck cancer	0.0019	0.00755	CcSEcCtD
Leflunomide—Oral candidiasis—Docetaxel—head and neck cancer	0.00182	0.00723	CcSEcCtD
Leflunomide—Hepatic failure—Hydroxyurea—head and neck cancer	0.0018	0.00714	CcSEcCtD
Leflunomide—Nail disorder—Docetaxel—head and neck cancer	0.00178	0.00708	CcSEcCtD
Leflunomide—Herpes simplex—Fluorouracil—head and neck cancer	0.00174	0.0069	CcSEcCtD
Leflunomide—Cyst—Docetaxel—head and neck cancer	0.00173	0.00687	CcSEcCtD
Leflunomide—Liver disorder—Docetaxel—head and neck cancer	0.00169	0.00674	CcSEcCtD
Leflunomide—Ulcer—Fluorouracil—head and neck cancer	0.00169	0.00673	CcSEcCtD
Leflunomide—Neuralgia—Docetaxel—head and neck cancer	0.00166	0.00661	CcSEcCtD
Leflunomide—Inflammation—Fluorouracil—head and neck cancer	0.00165	0.00656	CcSEcCtD
Leflunomide—Interstitial lung disease—Docetaxel—head and neck cancer	0.00163	0.00649	CcSEcCtD
Leflunomide—Throat sore—Docetaxel—head and neck cancer	0.0016	0.00637	CcSEcCtD
Leflunomide—Oropharyngeal discomfort—Docetaxel—head and neck cancer	0.00159	0.00631	CcSEcCtD
Leflunomide—Dermatitis contact—Fluorouracil—head and neck cancer	0.00158	0.00629	CcSEcCtD
Leflunomide—Neuritis—Docetaxel—head and neck cancer	0.00155	0.00615	CcSEcCtD
Leflunomide—Hepatotoxicity—Docetaxel—head and neck cancer	0.0015	0.00595	CcSEcCtD
Leflunomide—Angina pectoris—Vinblastine—head and neck cancer	0.00149	0.00592	CcSEcCtD
Leflunomide—Oesophagitis—Fluorouracil—head and neck cancer	0.00146	0.00581	CcSEcCtD
Leflunomide—Breast disorder—Hydroxyurea—head and neck cancer	0.00146	0.0058	CcSEcCtD
Leflunomide—Rash maculo-papular—Fluorouracil—head and neck cancer	0.00145	0.00578	CcSEcCtD
Leflunomide—Pancytopenia—Vinblastine—head and neck cancer	0.00145	0.00577	CcSEcCtD
Leflunomide—Sepsis—Fluorouracil—head and neck cancer	0.00139	0.00552	CcSEcCtD
Leflunomide—DHODH—lymphoid tissue—head and neck cancer	0.00138	0.0975	CbGeAlD
Leflunomide—Pancreatitis—Hydroxyurea—head and neck cancer	0.00137	0.00544	CcSEcCtD
Leflunomide—Neuropathy peripheral—Vinblastine—head and neck cancer	0.00134	0.00531	CcSEcCtD
Leflunomide—Pancytopenia—Hydroxyurea—head and neck cancer	0.00132	0.00527	CcSEcCtD
Leflunomide—Neutropenia—Hydroxyurea—head and neck cancer	0.0013	0.00519	CcSEcCtD
Leflunomide—Dysuria—Hydroxyurea—head and neck cancer	0.0013	0.00519	CcSEcCtD
Leflunomide—Agranulocytosis—Vinblastine—head and neck cancer	0.00127	0.00506	CcSEcCtD
Leflunomide—Oropharyngeal pain—Docetaxel—head and neck cancer	0.00127	0.00505	CcSEcCtD
Leflunomide—DHODH—thyroid gland—head and neck cancer	0.00125	0.0885	CbGeAlD
Leflunomide—Infestation NOS—Hydroxyurea—head and neck cancer	0.00124	0.00494	CcSEcCtD
Leflunomide—Infestation—Hydroxyurea—head and neck cancer	0.00124	0.00494	CcSEcCtD
Leflunomide—Haemoglobin—Vinblastine—head and neck cancer	0.00123	0.00489	CcSEcCtD
Leflunomide—Haemorrhage—Vinblastine—head and neck cancer	0.00122	0.00487	CcSEcCtD
Leflunomide—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.00122	0.00485	CcSEcCtD
Leflunomide—Pharyngitis—Vinblastine—head and neck cancer	0.00122	0.00483	CcSEcCtD
Leflunomide—Stomatitis—Hydroxyurea—head and neck cancer	0.00121	0.00482	CcSEcCtD
Leflunomide—Bone pain—Docetaxel—head and neck cancer	0.00121	0.00479	CcSEcCtD
Leflunomide—PTK2B—connective tissue—head and neck cancer	0.00119	0.0844	CbGeAlD
Leflunomide—Inflammation—Docetaxel—head and neck cancer	0.00119	0.00473	CcSEcCtD
Leflunomide—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00118	0.00468	CcSEcCtD
Leflunomide—Osteoarthritis—Fluorouracil—head and neck cancer	0.00116	0.00462	CcSEcCtD
Leflunomide—Blood pressure increased—Docetaxel—head and neck cancer	0.00116	0.00459	CcSEcCtD
Leflunomide—Hepatocellular injury—Docetaxel—head and neck cancer	0.00116	0.00459	CcSEcCtD
Leflunomide—Haemoglobin—Hydroxyurea—head and neck cancer	0.00112	0.00446	CcSEcCtD
Leflunomide—Haemorrhage—Hydroxyurea—head and neck cancer	0.00112	0.00444	CcSEcCtD
Leflunomide—AHR—parotid gland—head and neck cancer	0.00112	0.0789	CbGeAlD
Leflunomide—DHODH—head—head and neck cancer	0.00111	0.0785	CbGeAlD
Leflunomide—Colitis—Docetaxel—head and neck cancer	0.00111	0.00441	CcSEcCtD
Leflunomide—Candida infection—Docetaxel—head and neck cancer	0.0011	0.00438	CcSEcCtD
Leflunomide—Alopecia—Vinblastine—head and neck cancer	0.00108	0.0043	CcSEcCtD
Leflunomide—AHR—saliva-secreting gland—head and neck cancer	0.00107	0.0756	CbGeAlD
Leflunomide—Dry skin—Fluorouracil—head and neck cancer	0.00106	0.00423	CcSEcCtD
Leflunomide—Oesophagitis—Docetaxel—head and neck cancer	0.00106	0.0042	CcSEcCtD
Leflunomide—Neoplasm—Docetaxel—head and neck cancer	0.00104	0.00415	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CASP8—head and neck cancer	0.00104	0.00407	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CDH1—head and neck cancer	0.00103	0.00403	CbGpPWpGaD
Leflunomide—PTK2B—Osteopontin-mediated events—PIK3CA—head and neck cancer	0.00102	0.00398	CbGpPWpGaD
Leflunomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00101	0.00396	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—STAT3—head and neck cancer	0.00101	0.00396	CbGpPWpGaD
Leflunomide—Sepsis—Docetaxel—head and neck cancer	0.001	0.00398	CcSEcCtD
Leflunomide—Chills—Hydroxyurea—head and neck cancer	0.001	0.00398	CcSEcCtD
Leflunomide—Eosinophilia—Fluorouracil—head and neck cancer	0.000994	0.00395	CcSEcCtD
Leflunomide—Ill-defined disorder—Vinblastine—head and neck cancer	0.000989	0.00393	CcSEcCtD
Leflunomide—PTK2B—IL-7 Signaling Pathway—AKT1—head and neck cancer	0.000987	0.00386	CbGpPWpGaD
Leflunomide—Alopecia—Hydroxyurea—head and neck cancer	0.000987	0.00392	CcSEcCtD
Leflunomide—Anaemia—Vinblastine—head and neck cancer	0.000985	0.00392	CcSEcCtD
Leflunomide—PTK2B—IL2-mediated signaling events—IL2—head and neck cancer	0.000983	0.00385	CbGpPWpGaD
Leflunomide—Angina pectoris—Fluorouracil—head and neck cancer	0.000978	0.00389	CcSEcCtD
Leflunomide—PTK2B—IL-2 Signaling Pathway—MAPK3—head and neck cancer	0.000967	0.00378	CbGpPWpGaD
Leflunomide—Malaise—Vinblastine—head and neck cancer	0.000961	0.00382	CcSEcCtD
Leflunomide—Vertigo—Vinblastine—head and neck cancer	0.000958	0.00381	CcSEcCtD
Leflunomide—Leukopenia—Vinblastine—head and neck cancer	0.000954	0.00379	CcSEcCtD
Leflunomide—Pancytopenia—Fluorouracil—head and neck cancer	0.000954	0.00379	CcSEcCtD
Leflunomide—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.000947	0.00371	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—PIK3CA—head and neck cancer	0.000945	0.0037	CbGpPWpGaD
Leflunomide—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000933	0.00371	CcSEcCtD
Leflunomide—Hepatic failure—Docetaxel—head and neck cancer	0.000933	0.00371	CcSEcCtD
Leflunomide—CYP2C9—Xenobiotics—CYP1A1—head and neck cancer	0.000927	0.00363	CbGpPWpGaD
Leflunomide—Hypertension—Vinblastine—head and neck cancer	0.00092	0.00366	CcSEcCtD
Leflunomide—PTK2B—IL-2 Signaling Pathway—MAPK1—head and neck cancer	0.00092	0.0036	CbGpPWpGaD
Leflunomide—CYP1A2—Estrogen metabolism—GSTM1—head and neck cancer	0.000909	0.00356	CbGpPWpGaD
Leflunomide—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000902	0.00358	CcSEcCtD
Leflunomide—Pneumonia—Fluorouracil—head and neck cancer	0.000901	0.00358	CcSEcCtD
Leflunomide—Anaemia—Hydroxyurea—head and neck cancer	0.000898	0.00357	CcSEcCtD
Leflunomide—Discomfort—Vinblastine—head and neck cancer	0.000897	0.00356	CcSEcCtD
Leflunomide—Infestation—Fluorouracil—head and neck cancer	0.000895	0.00356	CcSEcCtD
Leflunomide—Infestation NOS—Fluorouracil—head and neck cancer	0.000895	0.00356	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—BCL2—head and neck cancer	0.000894	0.0035	CbGpPWpGaD
Leflunomide—CYP2C9—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000892	0.00349	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—MAPK3—head and neck cancer	0.000883	0.00346	CbGpPWpGaD
Leflunomide—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000878	0.00349	CcSEcCtD
Leflunomide—Malaise—Hydroxyurea—head and neck cancer	0.000877	0.00348	CcSEcCtD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—HRAS—head and neck cancer	0.000874	0.00342	CbGpPWpGaD
Leflunomide—PTK2B—lymphoid tissue—head and neck cancer	0.000873	0.0617	CbGeAlD
Leflunomide—Stomatitis—Fluorouracil—head and neck cancer	0.000873	0.00347	CcSEcCtD
Leflunomide—Urinary tract infection—Fluorouracil—head and neck cancer	0.00087	0.00346	CcSEcCtD
Leflunomide—Conjunctivitis—Fluorouracil—head and neck cancer	0.00087	0.00346	CcSEcCtD
Leflunomide—Leukopenia—Hydroxyurea—head and neck cancer	0.00087	0.00346	CcSEcCtD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—CCND1—head and neck cancer	0.000869	0.0034	CbGpPWpGaD
Leflunomide—CYP1A2—Estrogen metabolism—CYP1A1—head and neck cancer	0.000862	0.00337	CbGpPWpGaD
Leflunomide—Thrombocytopenia—Vinblastine—head and neck cancer	0.000852	0.00339	CcSEcCtD
Leflunomide—Epistaxis—Fluorouracil—head and neck cancer	0.000845	0.00336	CcSEcCtD
Leflunomide—PTK2B—Interleukin-2 signaling—MAPK1—head and neck cancer	0.00084	0.00329	CbGpPWpGaD
Leflunomide—Sinusitis—Fluorouracil—head and neck cancer	0.00084	0.00334	CcSEcCtD
Leflunomide—Agranulocytosis—Fluorouracil—head and neck cancer	0.000836	0.00332	CcSEcCtD
Leflunomide—Anorexia—Vinblastine—head and neck cancer	0.000829	0.0033	CcSEcCtD
Leflunomide—PTK2B—FGF signaling pathway—STAT3—head and neck cancer	0.000827	0.00324	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—STAT3—head and neck cancer	0.000827	0.00324	CbGpPWpGaD
Leflunomide—Migraine—Docetaxel—head and neck cancer	0.000825	0.00328	CcSEcCtD
Leflunomide—AHR—trachea—head and neck cancer	0.000824	0.0583	CbGeAlD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000822	0.00327	CcSEcCtD
Leflunomide—Discomfort—Hydroxyurea—head and neck cancer	0.000818	0.00325	CcSEcCtD
Leflunomide—Haemoglobin—Fluorouracil—head and neck cancer	0.000808	0.00321	CcSEcCtD
Leflunomide—Rhinitis—Fluorouracil—head and neck cancer	0.000806	0.0032	CcSEcCtD
Leflunomide—Haemorrhage—Fluorouracil—head and neck cancer	0.000804	0.00319	CcSEcCtD
Leflunomide—Pharyngitis—Fluorouracil—head and neck cancer	0.000798	0.00317	CcSEcCtD
Leflunomide—PTK2B—thyroid gland—head and neck cancer	0.000793	0.0561	CbGeAlD
Leflunomide—CYP1A2—Xenobiotics—CYP1A1—head and neck cancer	0.000792	0.0031	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—MAPK3—head and neck cancer	0.00079	0.00309	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—MAPK3—head and neck cancer	0.00079	0.00309	CbGpPWpGaD
Leflunomide—Infection—Hydroxyurea—head and neck cancer	0.000788	0.00313	CcSEcCtD
Leflunomide—Paraesthesia—Vinblastine—head and neck cancer	0.000781	0.0031	CcSEcCtD
Leflunomide—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000778	0.00309	CcSEcCtD
Leflunomide—DHODH—lymph node—head and neck cancer	0.000778	0.055	CbGeAlD
Leflunomide—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000777	0.00309	CcSEcCtD
Leflunomide—Liver function test abnormal—Docetaxel—head and neck cancer	0.000774	0.00308	CcSEcCtD
Leflunomide—Skin disorder—Hydroxyurea—head and neck cancer	0.000771	0.00306	CcSEcCtD
Leflunomide—Dry skin—Docetaxel—head and neck cancer	0.000769	0.00306	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CCND1—head and neck cancer	0.000767	0.003	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—MAPK1—head and neck cancer	0.000763	0.00299	CbGpPWpGaD
Leflunomide—CYP1A2—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000762	0.00298	CbGpPWpGaD
Leflunomide—Breast disorder—Docetaxel—head and neck cancer	0.000758	0.00301	CcSEcCtD
Leflunomide—Anorexia—Hydroxyurea—head and neck cancer	0.000756	0.00301	CcSEcCtD
Leflunomide—Decreased appetite—Vinblastine—head and neck cancer	0.000756	0.00301	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000755	0.003	CcSEcCtD
Leflunomide—Cramp muscle—Docetaxel—head and neck cancer	0.000755	0.003	CcSEcCtD
Leflunomide—PTK2B—FGF signaling pathway—MAPK1—head and neck cancer	0.000752	0.00294	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—MAPK1—head and neck cancer	0.000752	0.00294	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—STAT3—head and neck cancer	0.000746	0.00292	CbGpPWpGaD
Leflunomide—Pain—Vinblastine—head and neck cancer	0.000744	0.00296	CcSEcCtD
Leflunomide—Constipation—Vinblastine—head and neck cancer	0.000744	0.00296	CcSEcCtD
Leflunomide—DHODH—Metabolism—NAT2—head and neck cancer	0.000741	0.0029	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—PTEN—head and neck cancer	0.00074	0.0029	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—VEGFA—head and neck cancer	0.000739	0.00289	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—HRAS—head and neck cancer	0.000738	0.00289	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—PIK3CA—head and neck cancer	0.000729	0.00285	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—VEGFA—head and neck cancer	0.00072	0.00282	CbGpPWpGaD
Leflunomide—Arrhythmia—Fluorouracil—head and neck cancer	0.000718	0.00285	CcSEcCtD
Leflunomide—Feeling abnormal—Vinblastine—head and neck cancer	0.000717	0.00285	CcSEcCtD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—STAT3—head and neck cancer	0.000713	0.00279	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000711	0.00283	CcSEcCtD
Leflunomide—Alopecia—Fluorouracil—head and neck cancer	0.00071	0.00282	CcSEcCtD
Leflunomide—Dyspnoea—Hydroxyurea—head and neck cancer	0.000707	0.00281	CcSEcCtD
Leflunomide—Angina pectoris—Docetaxel—head and neck cancer	0.000706	0.00281	CcSEcCtD
Leflunomide—PTK2B—head—head and neck cancer	0.000704	0.0498	CbGeAlD
Leflunomide—PTK2B—Endothelins—MAPK3—head and neck cancer	0.000699	0.00273	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—MAPK3—head and neck cancer	0.000699	0.00273	CbGpPWpGaD
Leflunomide—Dyspepsia—Hydroxyurea—head and neck cancer	0.000698	0.00278	CcSEcCtD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—head and neck cancer	0.000695	0.00272	CbGpPWpGaD
Leflunomide—Decreased appetite—Hydroxyurea—head and neck cancer	0.00069	0.00274	CcSEcCtD
Leflunomide—Pancytopenia—Docetaxel—head and neck cancer	0.000688	0.00274	CcSEcCtD
Leflunomide—Abdominal pain—Vinblastine—head and neck cancer	0.000688	0.00273	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000685	0.00272	CcSEcCtD
Leflunomide—Fatigue—Hydroxyurea—head and neck cancer	0.000684	0.00272	CcSEcCtD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—MAPK3—head and neck cancer	0.000682	0.00267	CbGpPWpGaD
Leflunomide—Constipation—Hydroxyurea—head and neck cancer	0.000678	0.0027	CcSEcCtD
Leflunomide—Pain—Hydroxyurea—head and neck cancer	0.000678	0.0027	CcSEcCtD
Leflunomide—Neutropenia—Docetaxel—head and neck cancer	0.000678	0.00269	CcSEcCtD
Leflunomide—PTK2B—Interleukin-2 signaling—HRAS—head and neck cancer	0.000675	0.00264	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—VEGFA—head and neck cancer	0.000669	0.00262	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—MAPK1—head and neck cancer	0.000665	0.0026	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—MAPK1—head and neck cancer	0.000665	0.0026	CbGpPWpGaD
Leflunomide—Vision blurred—Fluorouracil—head and neck cancer	0.000659	0.00262	CcSEcCtD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—MAPK3—head and neck cancer	0.000657	0.00257	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—EGFR—head and neck cancer	0.000656	0.00257	CbGpPWpGaD
Leflunomide—Weight decreased—Docetaxel—head and neck cancer	0.000656	0.00261	CcSEcCtD
Leflunomide—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000654	0.0026	CcSEcCtD
Leflunomide—PTK2B—FGF signaling pathway—PIK3CA—head and neck cancer	0.000653	0.00255	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—PIK3CA—head and neck cancer	0.000653	0.00255	CbGpPWpGaD
Leflunomide—AHR—thyroid gland—head and neck cancer	0.000652	0.0461	CbGeAlD
Leflunomide—PTK2B—IL-2 Signaling Pathway—AKT1—head and neck cancer	0.000652	0.00255	CbGpPWpGaD
Leflunomide—Pneumonia—Docetaxel—head and neck cancer	0.00065	0.00258	CcSEcCtD
Leflunomide—DHODH—Metabolism—DPYD—head and neck cancer	0.00065	0.00254	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—MAPK1—head and neck cancer	0.000648	0.00254	CbGpPWpGaD
Leflunomide—Anaemia—Fluorouracil—head and neck cancer	0.000647	0.00257	CcSEcCtD
Leflunomide—Infestation NOS—Docetaxel—head and neck cancer	0.000646	0.00257	CcSEcCtD
Leflunomide—Infestation—Docetaxel—head and neck cancer	0.000646	0.00257	CcSEcCtD
Leflunomide—Hypersensitivity—Vinblastine—head and neck cancer	0.000641	0.00255	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000641	0.00255	CcSEcCtD
Leflunomide—PTK2B—Cell-Cell communication—CDH1—head and neck cancer	0.000637	0.00249	CbGpPWpGaD
Leflunomide—Renal failure—Docetaxel—head and neck cancer	0.000635	0.00252	CcSEcCtD
Leflunomide—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000633	0.00252	CcSEcCtD
Leflunomide—Stomatitis—Docetaxel—head and neck cancer	0.00063	0.0025	CcSEcCtD
Leflunomide—Jaundice—Docetaxel—head and neck cancer	0.00063	0.0025	CcSEcCtD
Leflunomide—Conjunctivitis—Docetaxel—head and neck cancer	0.000628	0.0025	CcSEcCtD
Leflunomide—Body temperature increased—Hydroxyurea—head and neck cancer	0.000627	0.00249	CcSEcCtD
Leflunomide—Leukopenia—Fluorouracil—head and neck cancer	0.000626	0.00249	CcSEcCtD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—MAPK1—head and neck cancer	0.000625	0.00245	CbGpPWpGaD
Leflunomide—Asthenia—Vinblastine—head and neck cancer	0.000624	0.00248	CcSEcCtD
Leflunomide—DHODH—Metabolism—YAP1—head and neck cancer	0.000617	0.00241	CbGpPWpGaD
Leflunomide—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000611	0.00243	CcSEcCtD
Leflunomide—Epistaxis—Docetaxel—head and neck cancer	0.00061	0.00242	CcSEcCtD
Leflunomide—PTK2B—IL2-mediated signaling events—HRAS—head and neck cancer	0.000604	0.00236	CbGpPWpGaD
Leflunomide—Agranulocytosis—Docetaxel—head and neck cancer	0.000603	0.0024	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—MAPK1—head and neck cancer	0.000602	0.00235	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—EGFR—head and neck cancer	0.000602	0.00235	CbGpPWpGaD
Leflunomide—Myalgia—Fluorouracil—head and neck cancer	0.000596	0.00237	CcSEcCtD
Leflunomide—Chest pain—Fluorouracil—head and neck cancer	0.000596	0.00237	CcSEcCtD
Leflunomide—Diarrhoea—Vinblastine—head and neck cancer	0.000595	0.00237	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—PTEN—head and neck cancer	0.000589	0.0023	CbGpPWpGaD
Leflunomide—CYP1A2—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.000589	0.0023	CbGpPWpGaD
Leflunomide—Discomfort—Fluorouracil—head and neck cancer	0.000589	0.00234	CcSEcCtD
Leflunomide—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000585	0.00232	CcSEcCtD
Leflunomide—Haemoglobin—Docetaxel—head and neck cancer	0.000583	0.00232	CcSEcCtD
Leflunomide—Rhinitis—Docetaxel—head and neck cancer	0.000582	0.00231	CcSEcCtD
Leflunomide—PTK2B—CXCR4-mediated signaling events—STAT3—head and neck cancer	0.000581	0.00227	CbGpPWpGaD
Leflunomide—Haemorrhage—Docetaxel—head and neck cancer	0.00058	0.00231	CcSEcCtD
Leflunomide—Hepatitis—Docetaxel—head and neck cancer	0.00058	0.00231	CcSEcCtD
Leflunomide—PTK2B—Integrins in angiogenesis—PIK3CA—head and neck cancer	0.000577	0.00226	CbGpPWpGaD
Leflunomide—Pharyngitis—Docetaxel—head and neck cancer	0.000576	0.00229	CcSEcCtD
Leflunomide—Dizziness—Vinblastine—head and neck cancer	0.000575	0.00229	CcSEcCtD
Leflunomide—Urinary tract disorder—Docetaxel—head and neck cancer	0.000573	0.00228	CcSEcCtD
Leflunomide—Oedema peripheral—Docetaxel—head and neck cancer	0.000572	0.00227	CcSEcCtD
Leflunomide—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000571	0.00227	CcSEcCtD
Leflunomide—Connective tissue disorder—Docetaxel—head and neck cancer	0.00057	0.00227	CcSEcCtD
Leflunomide—Asthenia—Hydroxyurea—head and neck cancer	0.000569	0.00226	CcSEcCtD
Leflunomide—Urethral disorder—Docetaxel—head and neck cancer	0.000569	0.00226	CcSEcCtD
Leflunomide—Infection—Fluorouracil—head and neck cancer	0.000567	0.00225	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—IL2—head and neck cancer	0.000565	0.00221	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—VEGFA—head and neck cancer	0.000562	0.0022	CbGpPWpGaD
Leflunomide—Nervous system disorder—Fluorouracil—head and neck cancer	0.00056	0.00223	CcSEcCtD
Leflunomide—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000559	0.00222	CcSEcCtD
Leflunomide—Tachycardia—Fluorouracil—head and neck cancer	0.000557	0.00222	CcSEcCtD
Leflunomide—Vomiting—Vinblastine—head and neck cancer	0.000553	0.0022	CcSEcCtD
Leflunomide—Erythema multiforme—Docetaxel—head and neck cancer	0.000549	0.00218	CcSEcCtD
Leflunomide—Headache—Vinblastine—head and neck cancer	0.000545	0.00217	CcSEcCtD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—TP53—head and neck cancer	0.000544	0.00213	CbGpPWpGaD
Leflunomide—Anorexia—Fluorouracil—head and neck cancer	0.000544	0.00216	CcSEcCtD
Leflunomide—Diarrhoea—Hydroxyurea—head and neck cancer	0.000543	0.00216	CcSEcCtD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—PIK3CA—head and neck cancer	0.000543	0.00212	CbGpPWpGaD
Leflunomide—Eye disorder—Docetaxel—head and neck cancer	0.000542	0.00215	CcSEcCtD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—head and neck cancer	0.000541	0.00212	CbGpPWpGaD
Leflunomide—Cardiac disorder—Docetaxel—head and neck cancer	0.000538	0.00214	CcSEcCtD
Leflunomide—PTK2B—Endothelins—HRAS—head and neck cancer	0.000534	0.00209	CbGpPWpGaD
Leflunomide—Hypotension—Fluorouracil—head and neck cancer	0.000534	0.00212	CcSEcCtD
Leflunomide—PTK2B—FGF signaling pathway—AKT1—head and neck cancer	0.000533	0.00209	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—HRAS—head and neck cancer	0.000527	0.00206	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—MAPK3—head and neck cancer	0.000525	0.00206	CbGpPWpGaD
Leflunomide—Dizziness—Hydroxyurea—head and neck cancer	0.000525	0.00209	CcSEcCtD
Leflunomide—Immune system disorder—Docetaxel—head and neck cancer	0.000524	0.00208	CcSEcCtD
Leflunomide—Mediastinal disorder—Docetaxel—head and neck cancer	0.000523	0.00208	CcSEcCtD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—HRAS—head and neck cancer	0.000521	0.00204	CbGpPWpGaD
Leflunomide—Chills—Docetaxel—head and neck cancer	0.000521	0.00207	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00052	0.00207	CcSEcCtD
Leflunomide—CYP1A2—Estrogen Receptor Pathway—STAT3—head and neck cancer	0.000519	0.00203	CbGpPWpGaD
Leflunomide—Arrhythmia—Docetaxel—head and neck cancer	0.000518	0.00206	CcSEcCtD
Leflunomide—CYP1A2—Phase II conjugation—NAT2—head and neck cancer	0.000517	0.00202	CbGpPWpGaD
Leflunomide—Nausea—Vinblastine—head and neck cancer	0.000517	0.00205	CcSEcCtD
Leflunomide—Insomnia—Fluorouracil—head and neck cancer	0.000516	0.00205	CcSEcCtD
Leflunomide—Paraesthesia—Fluorouracil—head and neck cancer	0.000513	0.00204	CcSEcCtD
Leflunomide—Alopecia—Docetaxel—head and neck cancer	0.000513	0.00204	CcSEcCtD
Leflunomide—Dyspnoea—Fluorouracil—head and neck cancer	0.000509	0.00202	CcSEcCtD
Leflunomide—Mental disorder—Docetaxel—head and neck cancer	0.000508	0.00202	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—TP53—head and neck cancer	0.000505	0.00198	CbGpPWpGaD
Leflunomide—Malnutrition—Docetaxel—head and neck cancer	0.000505	0.00201	CcSEcCtD
Leflunomide—Vomiting—Hydroxyurea—head and neck cancer	0.000504	0.002	CcSEcCtD
Leflunomide—Dyspepsia—Fluorouracil—head and neck cancer	0.000503	0.002	CcSEcCtD
Leflunomide—Rash—Hydroxyurea—head and neck cancer	0.0005	0.00199	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—MAPK1—head and neck cancer	0.0005	0.00196	CbGpPWpGaD
Leflunomide—Dermatitis—Hydroxyurea—head and neck cancer	0.0005	0.00199	CcSEcCtD
Leflunomide—Headache—Hydroxyurea—head and neck cancer	0.000497	0.00198	CcSEcCtD
Leflunomide—Decreased appetite—Fluorouracil—head and neck cancer	0.000496	0.00197	CcSEcCtD
Leflunomide—Dysgeusia—Docetaxel—head and neck cancer	0.000495	0.00197	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000493	0.00196	CcSEcCtD
Leflunomide—PTK2B—lymph node—head and neck cancer	0.000493	0.0348	CbGeAlD
Leflunomide—Back pain—Docetaxel—head and neck cancer	0.000489	0.00194	CcSEcCtD
Leflunomide—Pain—Fluorouracil—head and neck cancer	0.000488	0.00194	CcSEcCtD
Leflunomide—Muscle spasms—Docetaxel—head and neck cancer	0.000486	0.00193	CcSEcCtD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—AKT1—head and neck cancer	0.000484	0.00189	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—VEGFA—head and neck cancer	0.000484	0.00189	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—STAT3—head and neck cancer	0.000475	0.00186	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—AKT1—head and neck cancer	0.000471	0.00184	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—AKT1—head and neck cancer	0.000471	0.00184	CbGpPWpGaD
Leflunomide—Nausea—Hydroxyurea—head and neck cancer	0.000471	0.00187	CcSEcCtD
Leflunomide—Feeling abnormal—Fluorouracil—head and neck cancer	0.000471	0.00187	CcSEcCtD
Leflunomide—Anaemia—Docetaxel—head and neck cancer	0.000467	0.00186	CcSEcCtD
Leflunomide—PTK2B—LPA receptor mediated events—AKT1—head and neck cancer	0.000465	0.00182	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—AKT1—head and neck cancer	0.00046	0.0018	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—PIK3CA—head and neck cancer	0.000458	0.00179	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—MAPK3—head and neck cancer	0.000457	0.00179	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—VEGFA—head and neck cancer	0.000456	0.00179	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—MAPK3—head and neck cancer	0.000454	0.00178	CbGpPWpGaD
Leflunomide—Urticaria—Fluorouracil—head and neck cancer	0.000454	0.0018	CcSEcCtD
Leflunomide—Leukopenia—Docetaxel—head and neck cancer	0.000452	0.0018	CcSEcCtD
Leflunomide—Body temperature increased—Fluorouracil—head and neck cancer	0.000451	0.00179	CcSEcCtD
Leflunomide—CYP2C9—Arachidonic acid metabolism—GPX1—head and neck cancer	0.00045	0.00176	CbGpPWpGaD
Leflunomide—Palpitations—Docetaxel—head and neck cancer	0.000446	0.00177	CcSEcCtD
Leflunomide—CYP2C9—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000445	0.00174	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—head and neck cancer	0.000443	0.00173	CbGpPWpGaD
Leflunomide—Cough—Docetaxel—head and neck cancer	0.000441	0.00175	CcSEcCtD
Leflunomide—Hypertension—Docetaxel—head and neck cancer	0.000436	0.00173	CcSEcCtD
Leflunomide—ABCG2—Fluoropyrimidine Activity—TP53—head and neck cancer	0.000435	0.0017	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—MAPK1—head and neck cancer	0.000435	0.0017	CbGpPWpGaD
Leflunomide—ABCG2—parotid gland—head and neck cancer	0.000433	0.0306	CbGeAlD
Leflunomide—PTK2B—Signaling by Interleukins—MAPK1—head and neck cancer	0.000432	0.00169	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—MAPK3—head and neck cancer	0.000432	0.00169	CbGpPWpGaD
Leflunomide—Arthralgia—Docetaxel—head and neck cancer	0.00043	0.00171	CcSEcCtD
Leflunomide—Chest pain—Docetaxel—head and neck cancer	0.00043	0.00171	CcSEcCtD
Leflunomide—Myalgia—Docetaxel—head and neck cancer	0.00043	0.00171	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000427	0.0017	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—AKT1—head and neck cancer	0.000427	0.00167	CbGpPWpGaD
Leflunomide—Hypersensitivity—Fluorouracil—head and neck cancer	0.000421	0.00167	CcSEcCtD
Leflunomide—Dry mouth—Docetaxel—head and neck cancer	0.00042	0.00167	CcSEcCtD
Leflunomide—ABCG2—saliva-secreting gland—head and neck cancer	0.000415	0.0293	CbGeAlD
Leflunomide—Anaphylactic shock—Docetaxel—head and neck cancer	0.000412	0.00164	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—MAPK1—head and neck cancer	0.000411	0.00161	CbGpPWpGaD
Leflunomide—Infection—Docetaxel—head and neck cancer	0.000409	0.00163	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—head and neck cancer	0.000407	0.00159	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—head and neck cancer	0.000407	0.00159	CbGpPWpGaD
Leflunomide—CYP1A2—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000407	0.00159	CbGpPWpGaD
Leflunomide—AHR—lymph node—head and neck cancer	0.000405	0.0286	CbGeAlD
Leflunomide—Nervous system disorder—Docetaxel—head and neck cancer	0.000404	0.00161	CcSEcCtD
Leflunomide—Pruritus—Fluorouracil—head and neck cancer	0.000404	0.00161	CcSEcCtD
Leflunomide—Thrombocytopenia—Docetaxel—head and neck cancer	0.000404	0.0016	CcSEcCtD
Leflunomide—Tachycardia—Docetaxel—head and neck cancer	0.000402	0.0016	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—TP53—head and neck cancer	0.000402	0.00157	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—HRAS—head and neck cancer	0.000401	0.00157	CbGpPWpGaD
Leflunomide—Skin disorder—Docetaxel—head and neck cancer	0.0004	0.00159	CcSEcCtD
Leflunomide—Anorexia—Docetaxel—head and neck cancer	0.000393	0.00156	CcSEcCtD
Leflunomide—Diarrhoea—Fluorouracil—head and neck cancer	0.000391	0.00155	CcSEcCtD
Leflunomide—Hypotension—Docetaxel—head and neck cancer	0.000385	0.00153	CcSEcCtD
Leflunomide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000385	0.00151	CbGpPWpGaD
Leflunomide—CYP1A2—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000385	0.0015	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—PTEN—head and neck cancer	0.000384	0.0015	CbGpPWpGaD
Leflunomide—CYP1A2—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000381	0.00149	CbGpPWpGaD
Leflunomide—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.00038	0.00149	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—PIK3CA—head and neck cancer	0.000378	0.00148	CbGpPWpGaD
Leflunomide—Dizziness—Fluorouracil—head and neck cancer	0.000378	0.0015	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—STAT3—head and neck cancer	0.000378	0.00148	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000376	0.00149	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—PIK3CA—head and neck cancer	0.000375	0.00147	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—AKT1—head and neck cancer	0.000374	0.00146	CbGpPWpGaD
Leflunomide—Insomnia—Docetaxel—head and neck cancer	0.000373	0.00148	CcSEcCtD
Leflunomide—DHODH—Metabolism—TYMS—head and neck cancer	0.00037	0.00145	CbGpPWpGaD
Leflunomide—Paraesthesia—Docetaxel—head and neck cancer	0.00037	0.00147	CcSEcCtD
Leflunomide—Dyspnoea—Docetaxel—head and neck cancer	0.000367	0.00146	CcSEcCtD
Leflunomide—DHODH—Metabolism—GSTM1—head and neck cancer	0.000366	0.00143	CbGpPWpGaD
Leflunomide—Vomiting—Fluorouracil—head and neck cancer	0.000363	0.00144	CcSEcCtD
Leflunomide—Dyspepsia—Docetaxel—head and neck cancer	0.000363	0.00144	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—MAPK3—head and neck cancer	0.000361	0.00141	CbGpPWpGaD
Leflunomide—Rash—Fluorouracil—head and neck cancer	0.00036	0.00143	CcSEcCtD
Leflunomide—Dermatitis—Fluorouracil—head and neck cancer	0.00036	0.00143	CcSEcCtD
Leflunomide—Decreased appetite—Docetaxel—head and neck cancer	0.000358	0.00142	CcSEcCtD
Leflunomide—Headache—Fluorouracil—head and neck cancer	0.000358	0.00142	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—PIK3CA—head and neck cancer	0.000356	0.00139	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000356	0.00141	CcSEcCtD
Leflunomide—Fatigue—Docetaxel—head and neck cancer	0.000355	0.00141	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—AKT1—head and neck cancer	0.000354	0.00139	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—NAT2—head and neck cancer	0.000354	0.00139	CbGpPWpGaD
Leflunomide—Constipation—Docetaxel—head and neck cancer	0.000352	0.0014	CcSEcCtD
Leflunomide—Pain—Docetaxel—head and neck cancer	0.000352	0.0014	CcSEcCtD
Leflunomide—DHODH—Metabolism—GPX1—head and neck cancer	0.000351	0.00137	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—HRAS—head and neck cancer	0.000349	0.00137	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—NAT2—head and neck cancer	0.000349	0.00137	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CYP1A1—head and neck cancer	0.000347	0.00136	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—HRAS—head and neck cancer	0.000347	0.00136	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—STAT3—head and neck cancer	0.000344	0.00134	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—MAPK1—head and neck cancer	0.000343	0.00134	CbGpPWpGaD
Leflunomide—Feeling abnormal—Docetaxel—head and neck cancer	0.00034	0.00135	CcSEcCtD
Leflunomide—Nausea—Fluorouracil—head and neck cancer	0.000339	0.00135	CcSEcCtD
Leflunomide—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000337	0.00134	CcSEcCtD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	0.000331	0.00129	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—HRAS—head and neck cancer	0.00033	0.00129	CbGpPWpGaD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000329	0.00129	CbGpPWpGaD
Leflunomide—Abdominal pain—Docetaxel—head and neck cancer	0.000326	0.0013	CcSEcCtD
Leflunomide—Body temperature increased—Docetaxel—head and neck cancer	0.000326	0.0013	CcSEcCtD
Leflunomide—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000325	0.00127	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000324	0.00127	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—PIK3CA—head and neck cancer	0.000323	0.00126	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—STAT6—head and neck cancer	0.000314	0.00123	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—MAPK1—head and neck cancer	0.000312	0.00122	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—EGFR—head and neck cancer	0.000312	0.00122	CbGpPWpGaD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000312	0.00122	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—AKT1—head and neck cancer	0.000309	0.00121	CbGpPWpGaD
Leflunomide—Hypersensitivity—Docetaxel—head and neck cancer	0.000304	0.00121	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—NAT2—head and neck cancer	0.000303	0.00118	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—NAT2—head and neck cancer	0.000298	0.00117	CbGpPWpGaD
Leflunomide—Asthenia—Docetaxel—head and neck cancer	0.000296	0.00118	CcSEcCtD
Leflunomide—Pruritus—Docetaxel—head and neck cancer	0.000292	0.00116	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—AKT1—head and neck cancer	0.000291	0.00114	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—UROD—head and neck cancer	0.000289	0.00113	CbGpPWpGaD
Leflunomide—Diarrhoea—Docetaxel—head and neck cancer	0.000282	0.00112	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—HRAS—head and neck cancer	0.000276	0.00108	CbGpPWpGaD
Leflunomide—Dizziness—Docetaxel—head and neck cancer	0.000273	0.00108	CcSEcCtD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000267	0.00104	CbGpPWpGaD
Leflunomide—CYP2C9—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000265	0.00104	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL2—head and neck cancer	0.000264	0.00103	CbGpPWpGaD
Leflunomide—Vomiting—Docetaxel—head and neck cancer	0.000262	0.00104	CcSEcCtD
Leflunomide—Rash—Docetaxel—head and neck cancer	0.00026	0.00103	CcSEcCtD
Leflunomide—Dermatitis—Docetaxel—head and neck cancer	0.00026	0.00103	CcSEcCtD
Leflunomide—Headache—Docetaxel—head and neck cancer	0.000258	0.00103	CcSEcCtD
Leflunomide—CYP1A2—Phase II conjugation—GSTM1—head and neck cancer	0.000255	0.000999	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KISS1—head and neck cancer	0.000254	0.000992	CbGpPWpGaD
Leflunomide—ABCG2—thyroid gland—head and neck cancer	0.000253	0.0179	CbGeAlD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—HRAS—head and neck cancer	0.000251	0.000981	CbGpPWpGaD
Leflunomide—Nausea—Docetaxel—head and neck cancer	0.000245	0.000973	CcSEcCtD
Leflunomide—CYP1A2—thyroid gland—head and neck cancer	0.000243	0.0172	CbGeAlD
Leflunomide—PTK2B—BDNF signaling pathway—AKT1—head and neck cancer	0.000243	0.000952	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—head and neck cancer	0.000242	0.000947	CbGpPWpGaD
Leflunomide—CYP1A2—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000226	0.000886	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	0.000224	0.000877	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—STAT3—head and neck cancer	0.000222	0.000868	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—AKT1—head and neck cancer	0.000221	0.000866	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—MAPK3—head and neck cancer	0.000212	0.000829	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	0.000211	0.000826	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—GRP—head and neck cancer	0.000209	0.000817	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PTGS2—head and neck cancer	0.000206	0.000807	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—STAT6—head and neck cancer	0.000203	0.000793	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—MAPK1—head and neck cancer	0.000202	0.000789	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—head and neck cancer	0.000191	0.000746	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PTEN—head and neck cancer	0.00018	0.000704	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—YAP1—head and neck cancer	0.000179	0.000702	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PIK3CA—head and neck cancer	0.000175	0.000684	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	0.000175	0.000684	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	0.000172	0.000675	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	0.000172	0.000671	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	0.000172	0.000671	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	0.000172	0.000671	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	0.000166	0.000649	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000164	0.00064	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HRAS—head and neck cancer	0.000162	0.000633	CbGpPWpGaD
Leflunomide—ABCG2—lymph node—head and neck cancer	0.000157	0.0111	CbGeAlD
Leflunomide—CYP1A2—Biological oxidations—GSTM1—head and neck cancer	0.000149	0.000585	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—GSTM1—head and neck cancer	0.000147	0.000577	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—UROD—head and neck cancer	0.000146	0.000571	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—CYP1A1—head and neck cancer	0.000142	0.000554	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP1A1—head and neck cancer	0.00014	0.000547	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—BCL2L1—head and neck cancer	0.000139	0.000545	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	0.000138	0.000539	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PIK3CA—head and neck cancer	0.000127	0.000497	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—UROD—head and neck cancer	0.000125	0.000488	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NAT2—head and neck cancer	0.00012	0.000469	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CASP8—head and neck cancer	0.000114	0.000446	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000113	0.000443	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDH1—head and neck cancer	0.000113	0.00044	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—DPYD—head and neck cancer	0.000105	0.000411	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—AKT1—head and neck cancer	0.000104	0.000406	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—YAP1—head and neck cancer	9.98e-05	0.00039	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—BCL2—head and neck cancer	9.78e-05	0.000382	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	9.67e-05	0.000378	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL2—head and neck cancer	8.61e-05	0.000337	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PTEN—head and neck cancer	8.1e-05	0.000317	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOTCH1—head and neck cancer	8.09e-05	0.000316	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—STAT3—head and neck cancer	7.24e-05	0.000283	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAPK3—head and neck cancer	6.92e-05	0.000271	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MAPK1—head and neck cancer	6.58e-05	0.000258	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGFR—head and neck cancer	6.58e-05	0.000258	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	6.43e-05	0.000252	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	6.37e-05	0.000249	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NAT2—head and neck cancer	6.06e-05	0.000237	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—TYMS—head and neck cancer	5.99e-05	0.000234	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTM1—head and neck cancer	5.92e-05	0.000232	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CA—head and neck cancer	5.71e-05	0.000224	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GPX1—head and neck cancer	5.67e-05	0.000222	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP1A1—head and neck cancer	5.61e-05	0.00022	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL2—head and neck cancer	5.57e-05	0.000218	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	5.5e-05	0.000215	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	5.44e-05	0.000213	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCND1—head and neck cancer	5.43e-05	0.000212	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—DPYD—head and neck cancer	5.31e-05	0.000208	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HRAS—head and neck cancer	5.29e-05	0.000207	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTEN—head and neck cancer	5.24e-05	0.000205	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NAT2—head and neck cancer	5.17e-05	0.000202	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—YAP1—head and neck cancer	5.04e-05	0.000197	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—head and neck cancer	4.73e-05	0.000185	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—STAT3—head and neck cancer	4.68e-05	0.000183	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AKT1—head and neck cancer	4.67e-05	0.000183	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—DPYD—head and neck cancer	4.54e-05	0.000178	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAPK3—head and neck cancer	4.47e-05	0.000175	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—YAP1—head and neck cancer	4.31e-05	0.000168	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAPK1—head and neck cancer	4.26e-05	0.000167	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGFR—head and neck cancer	4.26e-05	0.000167	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	3.79e-05	0.000148	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CA—head and neck cancer	3.69e-05	0.000145	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—head and neck cancer	3.57e-05	0.00014	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HRAS—head and neck cancer	3.42e-05	0.000134	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—head and neck cancer	3.34e-05	0.000131	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	3.3e-05	0.000129	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	3.24e-05	0.000127	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TYMS—head and neck cancer	3.03e-05	0.000118	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT1—head and neck cancer	3.02e-05	0.000118	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTM1—head and neck cancer	2.99e-05	0.000117	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTEN—head and neck cancer	2.91e-05	0.000114	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GPX1—head and neck cancer	2.86e-05	0.000112	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP1A1—head and neck cancer	2.84e-05	0.000111	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.82e-05	0.00011	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TYMS—head and neck cancer	2.59e-05	0.000101	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTM1—head and neck cancer	2.56e-05	0.0001	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GPX1—head and neck cancer	2.45e-05	9.58e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP1A1—head and neck cancer	2.42e-05	9.48e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.33e-05	9.11e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CA—head and neck cancer	2.05e-05	8.04e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.99e-05	7.79e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—head and neck cancer	1.69e-05	6.6e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKT1—head and neck cancer	1.68e-05	6.56e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTEN—head and neck cancer	1.47e-05	5.75e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—head and neck cancer	1.44e-05	5.64e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTEN—head and neck cancer	1.26e-05	4.92e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CA—head and neck cancer	1.04e-05	4.06e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CA—head and neck cancer	8.86e-06	3.47e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKT1—head and neck cancer	8.47e-06	3.32e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKT1—head and neck cancer	7.24e-06	2.83e-05	CbGpPWpGaD
